Identifying treatment targets and biomarkers for dry eye disease in cancer patients
2177GCCC: Identifying Novel Treatment Targets and Biomarkers for Ocular Surface Disease in Patients With Ocular Graft vs Host Disease (oGVHD) a Biobank Study
This study is trying to learn more about eye problems in cancer patients, especially those with a specific condition, by looking at their eyes over time and comparing them to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Maryland, Baltimore Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT04946721 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the immunologic changes occurring in the ocular surface of cancer patients, particularly those with ocular graft-versus-host disease (oGVHD). It involves two groups: pre-bone marrow transplant cancer patients who will be assessed every three months for two years, and normal control patients evaluated every six months. During each visit, standard care exams will be conducted, and biological specimens will be collected for further analysis. The goal is to better understand the ocular surface conditions in these patients over time.
Who should consider this trial
Good fit: Ideal candidates include adult cancer patients aged 18 and older who are visiting the Eye clinic at the University of Maryland.
Not a fit: Patients who have had significant ocular surgery or are part of vulnerable populations such as children or prisoners may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment options for patients suffering from dry eye disease related to cancer therapies.
How similar studies have performed: While this study focuses on a specific patient population, similar observational studies have shown promise in understanding ocular conditions in cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (≥ 18 years of age) who visit the Eye clinic either in the UMGCCC within the UMD Hospital or the UMD Faculty Physicians Ophthalmology Practice at the UMD Professional Building or satellite locations for initial visits or established visits. * The patient must be able to understand and sign and date the informed consent form approved by the IRB. Exclusion Criteria: * Vulnerable populations: neonates, children, prisoners, institutionalized individuals. * Inability or refusal to provide informed consent. * History of ocular surgery (except refractive surgery or cataract surgery)
Where this trial is running
Baltimore, Maryland
- Geenebaum Cancer Center, University of Maryland Medical Center — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Sarah Sunshine, MD — University of Maryland, Baltimore
- Study coordinator: Sarah B Sunshine, MD
- Email: ssunshine@som.umaryland.edu
- Phone: 667-214-1292
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.